| Literature DB >> 35365499 |
Terence Stephenson1, Benjamin Allin2, Manjula D Nugawela3, Natalia Rojas3, Emma Dalrymple3, Snehal Pinto Pereira4, Manas Soni5, Marian Knight2, Emily Y Cheung3, Isobel Heyman3, Roz Shafran3.
Abstract
OBJECTIVE: The aim of this study was to derive a research definition for 'Long COVID (post-COVID-19 condition)' in children and young people (CYP) to allow comparisons between research studies.Entities:
Keywords: COVID-19; adolescent health; child health
Mesh:
Year: 2022 PMID: 35365499 PMCID: PMC8983414 DOI: 10.1136/archdischild-2021-323624
Source DB: PubMed Journal: Arch Dis Child ISSN: 0003-9888 Impact factor: 4.920
Figure 1Consensus process. CYP, children and young people.
Summary of participants
| Registered for round one | Completing round one | Completing round two | Completing round three | Consensus meeting | |
| Lived Experience | 23 | 22 (96%) | 21 (95%) | 21 (100%) | 2 |
| Researcher/Combination | 50 | 43 (86%) | 36 (84%) | 31 (86%) | 11 |
| Service Delivery | 47 | 40 (85%) | 29 (73%) | 25 (86%) | 4 |
|
|
|
|
|
|
|
Delphi phase three—important and less important statements for the definition of post-COVID-19 condition
| Statement category | Statement | Important | Less important | ||
| Three-panel consensus important | Two-panel consensus important | One or no panel consensus important | Three or two-panel consensus unimportant | ||
| Testing | At least one positive COVID-19 test | √ | |||
| A positive PCR test for COVID-19 | √ | ||||
| A positive lateral flow test for COVID-19 | √ | ||||
| An antibody test for COVID-19 | √ | ||||
| Type of initial symptoms | Before or at the time of their COVID-19 test | √ | |||
| During which time they had at least one recorded fever | √ | ||||
| During which time they lost their sense of smell | √ | ||||
| During which time they lost their sense of taste | √ | ||||
| During which time they had a persistent cough | √ | ||||
| During which time they had headache | √ | ||||
| During which time they had unusual tiredness | √ | ||||
| During which time they had a sore throat | √ | ||||
| Number of initial symptoms | 1 symptom only at the time of testing | √ | |||
| 2 or more symptoms at the time of testing | √ | ||||
| 3 or more symptoms at the time of testing | √ | ||||
| 4 or more symptoms at the time of testing | √ | ||||
| 5 or more symptoms at the time of testing | √ | ||||
| Persisting physical symptoms | Persisting unusual tiredness | √ | |||
| Persisting headaches | √ | ||||
| Persisting unusual shortness of breath | √ | ||||
| Persisting loss of smell or taste | √ | ||||
| Persisting dizziness | √ | ||||
| 1 or more persisting physical symptoms | √ | ||||
| 2 or more persisting physical symptoms | √ | ||||
| 3 or more persisting physical symptoms | √ | ||||
| 4 or more persisting physical symptoms | √ | ||||
| 5 or more persisting physical symptoms | √ | ||||
| Persisting well-being symptoms | A young person experiences difficulties with emotions, concentration, behaviour or not being able to get on with other people | √ | |||
| A young person has had persistent symptoms of anxiety (worry) | √ | ||||
| A young person has had persistent symptoms of low mood (sadness) | √ | ||||
| A young person has had persistent problems with concentration | √ | ||||
| The young person’s emotional difficulties have occurred or become worse after COVID-19 infection | √ | ||||
| Duration | Persist for more than 1 month after initial testing* | √ | |||
| Persist for more than 3 months after initial testing | √ | ||||
| Persist for more than 6 months after initial testing | √ | ||||
| Persist for more than 1 month after initial testing and are from the list of common symptoms on page 4 (ie, unusual tiredness, headaches, shortness of breath, loss of smell or taste, dizziness) | √ | ||||
| Persist for more than 3 months after initial testing and are from the list of common symptoms on page 4 (ie, unusual tiredness, headaches, shortness of breath, loss of smell or taste, dizziness) | √ | ||||
| Persist for more than 6 months after initial testing and are from the list of common symptoms on page 4 (ie, unusual tiredness, headaches, shortness of breath, loss of smell or taste, dizziness) | √ | ||||
| Burden of symptoms | The young person has symptoms that continue or develop after COVID-19 which impact their physical, mental or social well-being | √ | |||
| The young person has symptoms that are interfering with some aspect of daily living (eg, school, work, home, relationships) | √ | ||||
| The young person can judge the level of interference with their life themselves | √ | ||||
| The level of interference is assessed by a professional | √ | ||||
| The impact of the symptoms on functioning is at least moderate† | √ | ||||
| Tests to exclude other diseases | Persisting COVID-19 antibodies | √ | |||
| A negative glandular fever (monospot, antibody or EBV PCR) test† | √ | ||||
| A normal full blood count | √ | ||||
| An abnormal full blood count | √ | ||||
| A normal full blood count, CRP, ESR, urea and electrolytes, creatinine, calcium, liver function tests, random blood glucose† | √ | ||||
| A normal full blood count, CRP, ESR, urea and electrolytes, creatinine, calcium, liver function tests, random blood glucose, creatine kinase, thyroid function tests, coeliac disease screen, ferritin, vitamin D | √ | ||||
Statements closer to three/two-panel consensus important were identified if the percentage of people in each panel rating 7–9 was closer to 70% and 1–3 was closer to <15%.
*Close to three-panel consensus important.
†Close to two-panel consensus important.
CRP, C reactive protein; EBV PCR, Epstein Barr virus polymerase chain reaction; ESR, erythrocyte sedimentation rate.
Statements where consensus for inclusion in the definition is achieved or close to consensus and discussed at the consensus meeting
| Statement | N (%) voting for inclusion | N (%) of CYP voting for inclusion | Decision |
|
| |||
| At least one positive COVID-19 test needed | 17 (100) | 6 (75)* | Include |
|
| |||
| The young person has symptoms that continue or develop after COVID-19 which impact their physical, mental or social well-being | 17 (100) | 8 (100) | Include |
| The young person has symptoms that are interfering with some aspect of daily living (eg, school, work, home, relationships) | 17 (100) | 7 (100)* | Include |
| The impact of the symptoms on functioning is at least moderate | 11 (65) | 0 (0) | Exclude |
|
| |||
| 1 or more persisting physical symptoms | 17 (100) | 7 (88)* | Include |
|
| |||
| Persist for a minimum duration of 12 weeks after initial testing even if symptoms waxed and waned over that period | 17 (100) | 7 (88)* | Include |
| Persist for more than 3 months after initial testing and are from the list of common symptoms (ie, unusual tiredness, headaches, shortness of breath, loss of smell or taste, dizziness) | 0 (0) | 0 (0) | Exclude |
| Persist for more than 1 month after initial testing | 0 (0) | 0 (0) | Exclude |
|
| |||
| A negative glandular fever (monospot, antibody or EBV PCR) test | 0 (0) | 1 (13) | Exclude |
| A normal full blood count, CRP, ESR, urea and electrolytes, creatinine, calcium, liver function tests, random blood glucose | 0 (0) | 0 (0) | Exclude |
*One CYP was unable to vote due to technical problems.
CRP, C reactive protein; CYP, children and young people; EBV PCR, Epstein Barr virus polymerase chain reaction.